Project Grant R01HL179317
Award Date 9/1/25
Completion Date 5/31/29
Dollars Obligated $777K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98109, USA
Similar Awards
- This Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) provides $814,209 to the Fred Hutchinson Cancer Center to support research on the use of targeted nanoparticles for in vivo hematopoietic stem cell gene therapy. The project aims to refine the target for hematopoietic stem cell gene therapy and develop a method to genetically modify these cells directly in the patient, which would improve the feasibility...
- The federal Project Grant award titled "NICHE-SPECIFIC ENDOTHELIAL MECHANISMS REGULATING THE EXTRAVASATION OF HEMATOPOIETIC STEM CELLS" is funded by the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837). The $734,607 award, effective May 1, 2025 through February 28, 2030, supports research at Boston Medical Center Corporation to elucidate the key endothelial mechanisms that direct circulating hematopoietic stem cells across the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $680,321 to the Fred Hutchinson Cancer Center in Seattle, Washington to conduct research on the role of the DLK1 protein in regulating hematopoietic stem cell (HSC) quiescence. The research aims to further assess the effects of DLK1 on HSC maintenance and expansion, and elucidate the mechanism by which DLK1 inhibits receptor-mediated...
- This $2,024,340 Project Grant was awarded on August 15, 2025 by the National Heart Lung and Blood Institute (NHLBI), part of the National Institutes of Health, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports a multi-year research effort at Boston Children's Hospital to optimize outcomes for hematopoietic stem cell transplantation (HCT), an essential treatment for high-risk non-malignant and malignant hematologic diseases. The research project...
- This $153,117 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of the recipient's independent research career as an academic hematopathology physician-scientist. The key objectives are to study hematopoietic stem and progenitor cell (HSPC) crosstalk and transplantation, with the overarching goal of improving HSPC transplantation outcomes. The award period runs from August 1, 2025 to July 31,...
- This Project Grant award of $125,532.00, provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), aims to investigate the disruption of the clonal architecture of human hematopoietic stem cells driven by high-effect somatic and germline genetic variants, and identify the resulting phenotypic changes that lead to impaired stem cell function and increased disease risk with aging. The research will utilize a mitochondrial lineage tracing...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357.00 to support research on the bone marrow microenvironment and its role in regulating blood cell production. The research, to be conducted by the Children's Hospital Medical Center in Cincinnati, Ohio, aims to define the spatial organization and specialized vascular microenvironments within the bone marrow that recruit and...
- This federal Project Grant award for $802,301, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Weill Medical College of Cornell University to investigate the mechanisms that control the bone marrow "niche" environment and its role in expanding mutated blood stem cells that increase the risk of cardiovascular disease and cancer. The research aims to identify signaling pathways that can be targeted to prevent...
- This $147,486 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research at the University of Southern California to investigate the heterogeneous intercellular signaling of hematopoietic stem and progenitor cells (HSPCs) and its changes around the circadian clock. The research aims to advance understanding of how HSPC cell-cell communication and gene expression patterns within the bone marrow microenvironment are...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $410,449 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The Leland Stanford Junior University (Stanford University) on August 1, 2025. The funding supports research to develop novel synthetic biology strategies that would enable the quantitative and dynamic regulation of growth factors and cytokines produced from human induced pluripotent stem cell-derived endothelial cells (iPSC-ECs). The goal...